“I think it’s really important that people keep signing up to these type of trials to push research forward.”
A trial looking at dovitinib to treat advanced transitional cell cancer that has spread
This trial was for people with transitional cell cancer that had spread into the surrounding tissue (locally advanced) or to another part of the body.
More about this trial
Chemotherapy is used to treat advanced transitional cell cancer. But sometimes the cancer comes back after treatment (relapsed). Or it continues to grow during treatment (refractory). So doctors are always looking for new ways to treat advanced transitional cell cancer.
Dovitinib is a type of biological therapy called a tyrosine kinase inhibitor (TKI). It works by blocking messages to cells that tell them to grow and divide. So, dovitinib might stop cancer cells from growing and spreading.
The aims of this study were to find
- if dovitinib helped people with advanced transitional cell cancer
- how safe it was for people with advanced transitional cell cancer
Summary of results
The trial team found that dovitinib didn’t work very well for people with advanced transitional cell carcinoma.
This was a phase 2 trial. 44 people took part and everyone had dovitinib.
There were 2 stages to this trial. At the end of the 1st stage the researchers looked at the overall number of people who had no sign of their cancer (
They found that only 1 person’s cancer had shrunk. So the decision was made to stop the trial.
The worst side effects were
- a drop in blood cells
- weakness and a lack of energy
The trial team concluded that dovitinib was safe for people with advanced transitional cell carcinoma. But by itself it didn’t work well enough.
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Dr John Chester
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer